Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy - Wikidata - awgldk - TriplyDB

Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy

Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy

http://www.wikidata.org/entity/Q36556345

about

Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways Next-generation sequencing: hype and hope for development of personalized radiation therapy?Is cancer a metabolic disease?Autophagy in malignant transformation and cancer progression p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker Degradation of mutant p53H175 protein by Zn(II) through autophagy.Mutant TP53 posttranslational modifications: challenges and opportunities.A low-carb diet kills tumor cells with a mutant p53 tumor suppressor gene: the Atkins diet suppresses tumor growth Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy.High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity Epigenetic linkage of aging, cancer and nutrition.The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.Bioinformatics analysis of the serine and glycine pathway in cancer cells Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells.Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.Li Fraumeni syndrome, cancer and senescence: a new hypothesis.Mutant p53 succumbs to starvation.Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy Autophagy: regulation and role in development mTOR plays a critical role in p53-induced oxidative kidney cell injury in HIVAN.Chaperone-mediated autophagy degrades mutant p53.Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.Mutant p53 in cancer: new functions and therapeutic opportunities.Targeting mutant p53 in cancer: a long road to precision therapy.Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.Manipulation of autophagy in cancer cells: an innovative strategy to fight drug resistance.Mitochondrial ASncmtRNA-1 and ASncmtRNA-2 as potent targets to inhibit tumor growth and metastasis in the RenCa murine renal adenocarcinoma model.Chaperone-mediated autophagy substrate proteins in cancer.Molecular dynamics of the full-length p53 monomer.An expanded role for Caveolin-1 in brain tumors.The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer.Cancer metabolism as a therapeutic target: finding the right target(s) in the context of tumor heterogeneity, evolution, and metabolic plasticity.Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors p53 shades of Hippo.New therapeutic strategies to treat human cancers expressing mutant p53 proteins.Emerging Roles of p53 Family Members in Glucose Metabolism.

P2860

Q26767396-8CC19524-4C44-4926-BE56-46872FB2CF36 Q26796485-1EC38DF6-6251-4FCA-ABE6-56B5FE2D0FD2 Q26852241-702A0147-8FCE-4C47-AF67-B2DE588E6B39 Q27000191-E65F07E8-6DA6-4B55-9A38-869A8147E963 Q28079390-3F4A25EA-2EA5-4FB0-89AA-223F808B9A33 Q33576879-17080C8E-D5F5-46FB-AC67-0C7345A5A1D7 Q33709136-B5EF20A1-24C6-4A49-80CB-441674773389 Q33818479-285F4BFE-1D39-427A-B819-0600CFE8ED92 Q34035645-7E3BC638-BB6D-4989-AF6D-D53A1BF491EC Q34245117-1D6EEF9F-36EB-4AE0-936D-C5F6F0DE4CCA Q34274477-FB3F42F4-17D7-499A-A785-E2168A555CD0 Q34457187-A5C5FBA3-EF2F-4728-A7FA-286BA25922B8 Q34786538-F021AB11-0245-46A2-ACF9-1939909A35B3 Q34956789-D5BEB788-F62F-43FF-9D79-31F98104FF9A Q35212701-D525A783-DB2C-4137-8D8A-9B903615B6A0 Q36260253-C6FBCB21-2FA7-44C6-9BDB-E656210D39AF Q36347205-13562208-F7FA-4623-ADB3-67D40EDB0DB3 Q36797708-4239A74C-C738-4695-80E6-355BC3C7F3BD Q36798042-674896CD-F804-4262-9473-C903138BCFB3 Q36823657-E36D998D-82CA-41F7-9498-3E40F83D7798 Q36907145-42ECD8E4-2A80-43B0-B619-ABCF02C3C048 Q37043057-AFCA6A36-D005-4C69-89F0-02CA3C60920C Q37093673-DB33372B-7D30-4D27-A1D1-26ABBB986A00 Q37098172-068DA4EB-E9CC-404A-A450-B0DF60BBA454 Q37656224-1219C76C-2778-4DE2-9952-1C0AA46C6D13 Q38197826-D458CA07-269C-4A91-BC42-1D0737780316 Q38997351-7E0BAB02-004D-4D9A-98ED-4063CBC7017C Q39005896-01D493FE-7EF3-4553-ADB1-7EFA5622642C Q39229004-4E14BAAD-49C0-4021-980D-35D944D098A4 Q39407829-FEDDBAE8-4757-4B91-82FD-8B62115B6BD0 Q41279453-73059A81-AE2A-4DB0-99DC-D37783E62205 Q41613132-D4116F71-1F2E-4358-A52C-258A9D21F58D Q42103308-00B417AF-5E17-46AA-A34A-7BCF67363428 Q42151945-3B2E773F-E7ED-4E0B-8D04-2BFFDC1964D0 Q42217101-020F40BF-055F-4628-8D84-E20CD737A2ED Q42245590-2067338F-E8AB-4DB4-ABC4-B93C9C86546C Q42323429-D59B196F-E023-4CD4-B63B-50E4B493FA3C Q47850800-BAFE47CE-A292-4697-A2AB-F62ACD298BAB Q49962911-52AE509B-9C5D-4621-A452-531C55727F66 Q52727888-98B6FD7E-D208-468D-96C0-E1FA0885B37A

P2860

Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy

http://www.wikidata.org/entity/Q36556345

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Dietary downregulation of muta ...... implications for tumor therapy

@ast

Dietary downregulation of muta ...... implications for tumor therapy

@en

type

label

Dietary downregulation of muta ...... implications for tumor therapy

@ast

Dietary downregulation of muta ...... implications for tumor therapy

@en

prefLabel

Dietary downregulation of muta ...... implications for tumor therapy

@ast

Dietary downregulation of muta ...... implications for tumor therapy

@en

P1433

Q36556345-F956FC7B-4A70-45AB-B37F-76DE226D205C

P1476

Q36556345-8B0BFDF3-789A-48D1-8BBE-7F642E8FE98D

P2093

Q36556345-12E2BA40-7F1F-4027-BA59-3CAB2EFEED44

Q36556345-2B4123ED-01AF-4B8D-8329-A433F6A3F7BE

Q36556345-50A5E7A9-9A77-4891-8A95-72153E4DD37D

Q36556345-526517E4-358C-4946-9833-EC04AB984769

Q36556345-63A490B9-614E-44EF-9BF8-A6ED03B8DE38

Q36556345-7211A115-FED2-41D5-BBFA-01871E546789

Q36556345-948D0052-A305-4839-816C-622A32F417E3

Q36556345-C080A933-7964-4BE8-93A5-9003D62BD5B1

Q36556345-C4F5C2C4-21D2-4CE9-8E1A-73E98D252821

Q36556345-CDA20DDD-16A4-4321-A7CD-F10CC27BF50A

P2860

Q36556345-06427D31-483B-46B7-A9BC-106545116804

Q36556345-077B4F85-2E61-451B-95E6-0D3527EF31D5

Q36556345-10C9D908-B712-46A1-9FC9-3479FE9A3B2E

Q36556345-1945DE39-C34D-43AB-9A50-F8C64DCD42C5

Q36556345-239E40A2-AF1B-4F4D-8FCC-4D89FFEFA0CF

Q36556345-32C6ACE4-83F6-4143-AF49-B46DF88D08EC

Q36556345-38535599-405E-4972-A3E5-39CAD6601047

Q36556345-38F4E207-99F0-4881-A963-804146734735

Q36556345-3ABFF7CA-DCEF-46A6-B232-D12A2C079DF6

Q36556345-418BF830-F1AC-4C29-8FA4-9A9C38643A76

P304

Q36556345-C5DC985E-8AD6-4493-8579-3DC4121D0AE6

P31

Q36556345-B3400BD4-1F52-4A25-9829-38E3FDE2741E

P356

Q36556345-54EFF67E-7B06-48F1-BE3F-5D0ABDF3D32B

P433

Q36556345-75F47B93-671C-4382-B839-559AB495D0A4

P478

Q36556345-5DE3F0EF-1693-43E3-894F-F32C5D350B63

P577

Q36556345-90FFC1F0-0D2A-404E-9BE6-E6E63ACD7434

P5875

Q36556345-7736DCF6-893E-4AA4-B9A2-5D7347C3F9DD

P698

Q36556345-0FDEF5BE-ED1E-417C-B26B-1B410EC09115

P932

Q36556345-12B35E3C-6DCB-453D-B9CA-F42D4615C280

P356

P1433

P1476

Dietary downregulation of muta ...... implications for tumor therapy

@en

P2093

Anju Preet

http://www.w3.org/2001/XMLSchema#string

Anton Wellstein

http://www.w3.org/2001/XMLSchema#string

Chris Albanese

http://www.w3.org/2001/XMLSchema#string

Eveline E Vietsch

http://www.w3.org/2001/XMLSchema#string

Jason Catania

http://www.w3.org/2001/XMLSchema#string

Jill Bargonetti

http://www.w3.org/2001/XMLSchema#string

Katherine Reynoso

http://www.w3.org/2001/XMLSchema#string

Maria Laura Avantaggiati

http://www.w3.org/2001/XMLSchema#string

Olga Catalina Rodriguez

http://www.w3.org/2001/XMLSchema#string

Sujatra Choudhury

http://www.w3.org/2001/XMLSchema#string

P2860

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Induction of autophagy and inhibition of tumorigenesis by beclin 1

Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome

ATP-citrate lyase links cellular metabolism to histone acetylation

Modes of p53 regulation

DRAM, a p53-induced modulator of autophagy, is critical for apoptosis

p53 and metabolism

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint

Potential therapeutic applications of autophagy

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

P304

4436-4446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CC.22778

http://www.w3.org/2001/XMLSchema#string

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233418122

http://www.w3.org/2001/XMLSchema#string

P698

23151455

http://www.w3.org/2001/XMLSchema#string

P932

3552926

http://www.w3.org/2001/XMLSchema#string